AstraZeneca net and sales surge; cost cuts are set
Article Abstract:
AstraZeneca PLC of the United Kingdom posted a 17 percent net profit increase in the fourth quarter to $1.43 billion from $1.22 billion last year. Revenue is up 14 percent to $7.15 billion from $6.29 billion. Strong financial growth is due to increased sales and tight cost controls with 3,000 layoffs or 4.6 percent of the 65,000 workforce.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
AstraZeneca posts 15% drop in net
Article Abstract:
Thrid-quarter net profit for British pharmaceutical firm AstraZeneca PLC declined 15% to $1.34 bil, due primarily to MedImmune acquisition costs totaling $212 mil and a restructuring charge of $146 mil. Sales rose by 10% to reach $7.15 bil.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Earnings jump at Glaxo, AstraZeneca
Article Abstract:
British pharmaceutical companies AstraZeneca PLC and GlaxoSmithKline PLC are reporting high profits on their best selling drugs. However, both have halted or delayed development on other drugs, affecting the price of shares.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Deutsche Bank sees hit on loans. Deutsche Bank posts 25% rise in net earnings
- Abstracts: SAP stock price, profit rebound on new products. SAP posts 9.9% rise in net profit
- Abstracts: Rapid internationalisation among entrepreneurial firms in Australia, Canada, Ireland and New Zealand: an extension to the network approach